Showing 4161-4170 of 8896 results for "".
- FDA Clears Accure Laser System for Acne Vulgarishttps://practicaldermatology.com/news/fda-clears-accure-laser-system-acne-vulgaris/2468432/The US Food and Drug Administration (FDA) cleared the Accure Laser System for the long-term treatment of patients with mild-to-severe inflammatory acne vulgaris, according to a press release from Accure Acne, Inc. "This achievement cannot be overstated," Acclure Acne co-founder, chairman o
- Cetaphil Launches Rebrand with Debut of ‘For Everyone’s Sensitive Skin’ Campaignhttps://practicaldermatology.com/news/cetaphil-launches-rebrand-with-debut-of-for-everyones-sensitive-skin-campaign/2468433/A popular skincare line debuts “For Everyone’s Sensitive Skin” campaign as part of a rebrand. Cetaphil announced a complete brand “restage,” in a press release earlier this week. The brand is revamping its 77-year-old image with a bold, refreshed visual upgrade. The goal of the rebrand is
- Study: R&R Complex Superior to Ceramide Moisturizer for Dermatoporosishttps://practicaldermatology.com/news/study-rr-complex-superior-ceramide-moisturizer-dermatoporosis/2468413/Results from a split-arm study suggest that use of a new product (ReFORM & RePAIR COMPLEX with TriHex Technology® [R&R]) resulted in more skin improvements than a ceramide moisturizer in patients with dermatoporosis (DP). Conducted over 24 weeks, the trial included 38 participants
- European Decentralized Regulatory Procedure Completed for Efinaconazolehttps://practicaldermatology.com/news/european-decentralized-regulatory-procedure-completed-efinaconazole/2468407/Almirall, S.A. announced the successful completion of the decentralized regulatory procedure in Europe for efinaconazole, a triazole antifungal compound indicated for the treatment of onychomycosis, under the trade name of Jublia®. The low binding affinity of efinaconazole topical to kerat
- Analysis: HS-Related Genetic Markers Predict Cardiometabolic Outcomeshttps://practicaldermatology.com/news/study-finds-hs-related-genetic-markers-predict-cardiometabolic-outcomes/2468406/A new cohort study suggests individuals with a high polygenic risk score (PRS) for hidradenitis suppurativa (HS) have an increased risk of developing coronary artery disease (CAD) and diabetes. Study researchers used data from 391,481 participants of European ancestry in the UK Biobank, e
- Long-Term Mortality in Epidermal Necrolysis Influenced by In-Hospital Complicationshttps://practicaldermatology.com/news/long-term-mortality-epidermal-necrolysis-influenced-hospital-complications/2468372/Epidermal necrolysis (EN) is associated with high in-hospital and post-discharge mortality rates, with comorbidities playing a significant role in outcomes. Researchers for the recent cohort study used French Health System data to characterize mortality and sequelae associated with EN, whi
- ISHRS to Host 32nd World Congress in Denver This Monthhttps://practicaldermatology.com/news/ishrs-host-32nd-world-congress-denver-month/2468370/From refinements in hair restoration surgical techniques to understanding the psychological and physiological aspects of hair loss, the latest research and concepts in hair growth and restoration will be presented by some of the world’s most renowned hair restoration experts when they convene in
- TRuE AD3: Ruxolitinib Safety and Efficacy Confirmed in Children with Atopic Dermatitishttps://practicaldermatology.com/news/52-week-study-validates-ruxolitinibs-safety-and-efficacy-in-children-with-ad/2468353/Ruxolitinib cream (RUX) demonstrated long-term safety and efficacy in children aged 2 to 11 with mild-to-moderate atopic dermatitis (AD), with over 60% of patients achieving clear or nearly clear skin, according to updated data presented recently at the 2024 European Academy of Dermatology and Ve
- Triple-Combination Acne Treatment Shows Equal Efficacy Across Sexeshttps://practicaldermatology.com/news/triple-combination-acne-treatment-shows-equal-efficacy-across-sexes/2468352/A post hoc analysis of two phase 3 studies showed clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel (CAB) had s
- SEEN Unveils New Conditionerhttps://practicaldermatology.com/news/seen-unveils-new-conditioner/2468329/SEEN Hair Care introduced its new Fragrance-Free Leave-In Conditioner that the company said is safe for sensitive and acne-prone skin and non-comedogenic and non-irritating. “This multitasking leave-in conditioner detangles hair while delivering lightweight hydration plus heat, pollution,